HOME >> BIOLOGY >> NEWS
Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting

Snowmass, Co. (September 9, 2004) Inflammatory Bowel Diseases, comprised of Crohn's Disease and ulcerative colitis, are for the most part incurable and their causes are still unknown. About 1 million Americans suffer from IBD and research around the world on new therapeutic strategies against IBD is being reported at a conference sponsored by the American Physiological Society.

Below are reports on three presentations.

  • Anti-adhesion therapy in the treatment of IBD Julian Panes and Josep M. Pique of the Gastroenterology Department of the Hospital Clinic Barcelona, Spain, note that the localization for leukocytes to inflammatory areas has key implications in the pathogenesis, diagnosis and treatment of IBD. A major effort has been directed toward identifying and characterizing the adhesion glycoproteins that enable leukocytes to bind to vascular endothelial cells. Drugs that specifically target adhesion molecules involved in leukocyte recruitment are effective in treating intestinal inflammation.

    They said that experimental models have shown that blockade of VLA-4, VCAM-1 and P-selectin afford significant amelioration of intestinal inflammation. In experimental models, response to adhesion molecule blockage varies according to the type of inflammatory intestinal condition. In humans VLA-4 immunoneutralization has been effective in inducing remission in Crohn's Disease, but no data is available for ulcerative colitis.

    The researchers call for experimental and clinical controlled trials comparing the effectiveness of different strategies of CAM blockade, and suggest that this therapeutic approach be compared with current therapies.

  • Platelet recruitment in intestinal inflammation modulated by ICAM-1, P-selectin, PSGL-1

    Researchers from LSU and the University of Muenster studied the mechanisms responsible for platelet-WBC and platelet-endothelial cell (EC) interactions that occur in exper
    '"/>



  • Contact: Mayer Resnick
    mresnick@the-aps.org
    301-634-7209
    American Physiological Society
    9-Sep-2004


    Page: 1 2 3

    Related biology news :

    1. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
    2. Novel approaches to current cellular therapies continue progress toward disease prevention
    3. Novel therapies show promise against myeloid leukemia
    4. Novel sensors help clear the air
    5. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
    6. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
    7. Novel therapeutic target identified in fight against Rheumatoid Arthritis
    8. Novel bacterium detoxifies chlorinated pollutants
    9. Novel flu vaccine shows promise in mice
    10. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician
    11. Novel method identifies hidden genes

    Post Your Comments:
    *Name:
    *Comment:
    *Email:


    (Date:8/17/2018)... ... August 16, 2018 , ... With increasing safety requirements, and ... research projects, are presenting multiple challenges. To be successful in such a competitive environment, ... different aspects of the multiple tasks needed to develop a new drug or to ...
    (Date:8/14/2018)... ... 2018 , ... Career fairs provide an ideal setting for ... at once. However, healthcare professionals often have hectic schedules with little spare time ... providers who wish to explore opportunities and learn about multiple employers from the ...
    (Date:8/14/2018)... ... August 14, 2018 , ... ... and commercialization, is announcing the keynote for their NAVIGATE2018 conference. , ... as keynote speaker for NAVIGATE2018 , Cognition’s annual user conference. An experienced ...
    Breaking Biology News(10 mins):
    (Date:7/25/2018)... ... July 25, 2018 , ... ... its state-of-the-art Digital Vivarium™ and Vium Cloud approach to accelerate preclinical drug discovery ... Officer. Additionally, the company announced the appointment of Jeff Caron to the newly ...
    (Date:7/25/2018)... ... 2018 , ... John McDonald, CEO of ClearObject , ... India Business Council (IIBC), an advocacy group to strengthen economic ties between Indiana ... McDonald joins an impressive roster of local and national business leaders from organizations ...
    (Date:7/24/2018)... Texas (PRWEB) , ... July 24, 2018 , ... Boval ... to support blood bank reagent suppliers. In Boval’s early days most of the ... were added to produce BSA for diagnostic purposes after gel cards changed that market ...
    (Date:7/22/2018)... ... 19, 2018 , ... Mitotech S.A, a Luxembourg based clinical ... 3 clinical program in Dry Eye Disease. Under the agreement Essex Bio-Investment will ... towards the first Phase 3 study starting as early as Fall 2018. ...
    Breaking Biology Technology:
    Cached News: